9.2 PROTOCOL REVIEW AND MONITORING SYSTEM Purpose The Scientific Review Committee (SRC) ensures that all cancer clinical trials conducted under the auspices of Vanderbilt-lngram Cancer Center (VICC) meet the committee's pre-defined standards of scientific design. The Committee is also responsible for assigning a priority score for each protocol that indicates the amount of Cancer Center support a particular protocol should receive. Protocols requiring full committee review are evaluated for appropriate scientific rationale, clearly defined specific aims, achievable study endpoints, a plausible biostatistical plan, feasibility issues, and a justifiable ability to accrue patients. These criteria exist to ensure that the study is conducted in accordance with scientific principles that will allow the scientific aims of the study to be met. This clearly sets the SRC's role apart from the IRB, which primarily concerned with patient safety, while the SRC is focused on sound science designed one day to be translated into better practice. While the SRC and IRB have separate and distinct functions, they complement each other by ensuring the overall integrity of the study from both scientific and patient protection viewpoints. The SRC also assists in determining the level of VICC support for a particular protocol;the IRB has no role in this determination.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
United States
Zip Code
Han, Ying; Signorello, Lisa B; Strom, Sara S et al. (2015) Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 136:1210-7
Sanders, Melinda E; Schuyler, Peggy A; Simpson, Jean F et al. (2015) Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol 28:662-9
Chaturvedi, R; de Sablet, T; Asim, M et al. (2015) Increased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase. Oncogene 34:3429-40
Vilgelm, Anna E; Pawlikowski, Jeff S; Liu, Yan et al. (2015) Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 75:181-93
Wei, Jinxiong; Noto, Jennifer M; Zaika, Elena et al. (2015) Bacterial CagA protein induces degradation of p53 protein in a p14ARF-dependent manner. Gut 64:1040-8
Carrillo, A M; Bouska, A; Arrate, M P et al. (2015) Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene 34:846-56
Balko, Justin M; Giltnane, Jennifer M; Wang, Kai et al. (2014) Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 4:232-45
Weeke, Peter; Mosley, Jonathan D; Hanna, David et al. (2014) Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol 63:1430-7
Cheng, Feixiong; Jia, Peilin; Wang, Quan et al. (2014) Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol Biol Evol 31:2156-69
Peng, Dun-Fa; Hu, Tian-Ling; Soutto, Mohammed et al. (2014) Loss of glutathione peroxidase 7 promotes TNF-?-induced NF-?B activation in Barrett's carcinogenesis. Carcinogenesis 35:1620-8

Showing the most recent 10 out of 1594 publications